These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells. Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441 [TBL] [Abstract][Full Text] [Related]
25. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Galietta LJ Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197 [TBL] [Abstract][Full Text] [Related]
26. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein]. Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675 [TBL] [Abstract][Full Text] [Related]
27. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Mitchell RM; Jones AM; Barry PJ Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080 [TBL] [Abstract][Full Text] [Related]
28. Tezacaftor for the treatment of cystic fibrosis. Sala MA; Jain M Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878 [TBL] [Abstract][Full Text] [Related]
29. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
30. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
31. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622 [No Abstract] [Full Text] [Related]
33. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Jennings MT; Flume PA Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963 [TBL] [Abstract][Full Text] [Related]
34. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
35. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367 [TBL] [Abstract][Full Text] [Related]